title: Studies on the mechanism by which prolactin regulates protein, RNA, and DNA synthesis in Nb2 node lymphoma cells.
abstract: Specific aspects of the prolactin stimulation of RNA, DNA and protein synthesis in the Nb2 node lymphoma cell line were determined. In time sequence studies the onset of the prolactin stimulation of the incorporation of radiolabeled precursors into these macromolecules was found to be 0.5-1 h for [3H]uridine incorporation into RNA, 1-2 h for [3H]leucine incorporation into protein, and 4-8 h for [3H]thymidine incorporation into DNA. The total DNA content of the cell cultures was increased by 12-18 hours after addition of prolactin. Amiloride, an inhibitor of the plasma-membrane-bound Na+/H+ antiporter, was found to inhibit the mitogenic effects of prolactin. Amiloride was also found to inhibit the prolactin stimulation of DNA, RNA and protein synthesis, thus suggesting that the initial regulation of the Na+/H+ antiporter may initiate these responses as well as the mitogenic effect of prolactin. In contrast, H-7, a drug which inhibits protein kinase C, had no effect on the magnitude of the prolactin stimulation of DNA, RNA or protein synthesis at a drug concentration (100 muM) that abolished the mitogenic effect of prolactin. The early effects of prolactin on RNA, DNA and protein synthesis would therefore appear not to involve an activation of protein kinase C.
authors.affiliation: Department of Physiology, Wayne State University School of Medicine, Detroit, MI 48201.
authors.forename: J A
authors.initials: JA
authors.lastname: Rillema
authors.forename: T M
authors.initials: TM
authors.lastname: Tarrant
authors.forename: B E
authors.initials: BE
authors.lastname: Linebaugh
mesh_terms: D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D000584:Amiloride / Q000494:pharmacology; D002352:Carrier Proteins / Q000502:physiology; D002455:Cell Division / Q000187:drug effects; D004273:DNA, Neoplasm / Q000096:biosynthesis*; D007546:Isoquinolines / Q000494:pharmacology; D008223:Lymphoma / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D010879:Piperazines / Q000494:pharmacology; D011388:Prolactin / Q000494:pharmacology*; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases / Q000378:metabolism; D012334:RNA, Neoplasm / Q000096:biosynthesis*; D017923:Sodium-Hydrogen Exchangers; D013997:Time Factors; D014407:Tumor Cells, Cultured
chemical_list: D002352:Carrier Proteins; D004273:DNA, Neoplasm; D007546:Isoquinolines; D009363:Neoplasm Proteins; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D012334:RNA, Neoplasm; D017923:Sodium-Hydrogen Exchangers; D000584:Amiloride; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D011388:Prolactin; D011494:Protein Kinases